Article Text

Download PDFPDF
Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer
  1. Sharon Marsh, PhD
  1. Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, Montreal, Quebec, Canada.
  1. Address correspondence and reprint requests to Sharon Marsh, PhD, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, 5000 rue Bélanger, Montreal, Quebec, Canada H1T 1C8. E-mail: smarsh{at}


Objectives: Taxane (paclitaxel or docetaxel) and platinum (cisplatin or carboplatin) chemotherapy is commonly used in the treatment of ovarian cancer. Despite an initial high response to therapy, the 5-year survival rate remains low. The identification of pharmacogenomic markers to identify patients unlikely to respond or at risk for severe toxicity will assist in the goal of individualizing ovarian cancer treatment.

Materials and Methods: Most studies have assessed single nucleotide polymorphisms from genes involved in the pharmacokinetics and pharmacodynamics of the drugs.

Results: Unfortunately, most markers identified have not been replicated in subsequent studies.

Conclusions: Other mechanisms of variability, including epigenetic control of gene expression and copy number variation, may play important roles. In addition, nongenetic influences such as concurrent medications, and physiological and environmental factors could also affect individual responses to taxane and platinum therapy.

  • Pharmacogenomics
  • Methylation
  • Polymorphism
  • Taxane
  • Platinum

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.